The hypothesized importance of coinfections in the pathogenesis of post-treatment Lyme disease syndrome (PTLDS) leads to the use of combined, ongoing antimicrobial treatment in many cases despite the absence of symptoms typical of the presence of infection with specific pathogens. Serum samples from 103 patients with suspected post-treatment Lyme disease syndrome were tested for the presence of antibodies to the major tick-borne pathogens , /, and . Although the presence of anti- antibodies was detected in 12.6% of the samples and anti- antibodies in 9.7% of the samples, the presence of antibodies against both pathogens in the same samples or anti- antibodies in the selected group of patients could not be confirmed. However, we were able to detect autoantibodies, mostly antinuclear, in 11.6% of the patients studied. Our results are in good agreement with previously published studies showing the presence of a wide spectrum of autoantibodies in some patients with complicated forms of Lyme disease and post-treatment Lyme disease syndrome, but they do not reveal a significant influence of co-infections on the development of PTLDS in the studied group of patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619037 | PMC |
http://dx.doi.org/10.3390/microorganisms9112217 | DOI Listing |
Front Antibiot
May 2024
Laboratory of Bacteriology, Rocky Mountain Laboratories, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, United States.
Recent reports from the Centers for Disease Control and Prevention approximate 500,000 cases of Lyme disease in the United States yearly, a significant economic burden on the healthcare system. The standard treatment for Lyme disease includes broad-spectrum antibiotics, which may be administered for extensive periods of time and result in significant impacts to the patient. Recently, we demonstrated that , the causative agent of Lyme disease, is uniquely dependent upon peptide acquisition via an oligopeptide transport (Opp) system.
View Article and Find Full Text PDFFront Antibiot
May 2024
Division of Emergency Medicine, Boston Children's Hospital and Harvard Medical School, Boston, MA, United States.
Background: The 2018 Infectious Disease Committee of the American Academy of Pediatrics stated that up to 3 weeks or less of doxycycline is safe in children of all ages. Our goal was to examine trends in doxycycline treatment for children with Lyme disease.
Methods: We assembled a prospective cohort of children aged 1 to 21 years with Lyme disease who presented to one of eight participating Pedi Lyme Net centers between 2015 and 2023.
Epidemiol Infect
January 2025
Department of Health Security, Infectious Diseases Control and Vaccination Unit, Finnish Institute for Health and Welfare (THL)Helsinki, Finland.
With climate change, the geographic distribution of some VBDs has expanded, highlighting the need for adaptation, and managing the risks associated with emergence in new areas. We conducted a questionnaire survey on the knowledge, attitudes, and practices (KAP) about vector-borne diseases (VBDs) among sample of Finnish residents. The questions were scored and the level of KAP was determined based on scoring as poor, fair, good, or excellent.
View Article and Find Full Text PDFEur J Neurol
January 2025
Department of Clinical Laboratory and Internal Medicine, National Center of Neurology and Psychiatry, Tokyo, Japan.
Background And Purpose: Clinical manifestations of Lyme borreliosis (LB), caused by Borrelia burgdorferi sensu lato (Bbsl), include erythema migrans, Lyme neuroborreliosis (LNB), carditis, and arthritis. LB is a notifiable disease in Japan with <30 surveillance-reported LB cases annually, predominately from Hokkaido Prefecture. However, LB, including LNB, may be under-diagnosed in Japan since diagnostic tests are not readily available.
View Article and Find Full Text PDFInt J Parasitol Parasites Wildl
April 2025
British Columbia Centre for Disease Control, 655 W 12th Ave, Vancouver, British Columbia, V5Z 4R4, Canada.
As per published literature, the tick is the primary Lyme disease vector in British Columbia (BC), while the tick species is the dominant vector on the East Coast of Canada, with no . presence seen in BC. However, a recent publication reported presence of in BC which initiated this study to determine the accuracy of the microscopic identification of ticks received in the BC Centre for Disease Control (BCCDC) Public Health Laboratory and compare morphologic methods to molecular methods.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!